191 related articles for article (PubMed ID: 32661327)
1. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer.
Xiao B; Luo J; Xie E; Kong L; Tang J; Liu D; Mao L; Sui Q; Li W; Hong Z; Pan Z; Jiang W; Ding PR
Eur J Hum Genet; 2020 Nov; 28(11):1555-1562. PubMed ID: 32661327
[TBL] [Abstract][Full Text] [Related]
2. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
[TBL] [Abstract][Full Text] [Related]
3. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
4. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
[TBL] [Abstract][Full Text] [Related]
5. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome.
Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Chung DC
Mod Pathol; 2017 Mar; 30(3):440-447. PubMed ID: 28059100
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
[TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
[TBL] [Abstract][Full Text] [Related]
8. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population.
West NP; Gallop N; Kaye D; Glover A; Young C; Hutchins GGA; Brockmoeller SF; Westwood AC; Rossington H; Quirke P;
Histopathology; 2021 Nov; 79(5):690-699. PubMed ID: 33872400
[TBL] [Abstract][Full Text] [Related]
12. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
13. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.
Pérez-Carbonell L; Alenda C; Payá A; Castillejo A; Barberá VM; Guillén C; Rojas E; Acame N; Gutiérrez-Aviñó FJ; Castells A; Llor X; Andreu M; Soto JL; Jover R
J Mol Diagn; 2010 Jul; 12(4):498-504. PubMed ID: 20489114
[TBL] [Abstract][Full Text] [Related]
14. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
[TBL] [Abstract][Full Text] [Related]
15. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
[TBL] [Abstract][Full Text] [Related]
16. Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation.
Hitchins MP
Fam Cancer; 2016 Jul; 15(3):413-22. PubMed ID: 26886015
[TBL] [Abstract][Full Text] [Related]
17. Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation.
Pinto D; Pinto C; Guerra J; Pinheiro M; Santos R; Vedeld HM; Yohannes Z; Peixoto A; Santos C; Pinto P; Lopes P; Lothe R; Lind GE; Henrique R; Teixeira MR
Cancer Med; 2018 Feb; 7(2):433-444. PubMed ID: 29341452
[TBL] [Abstract][Full Text] [Related]
18. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort.
Dong L; Jin X; Wang W; Ye Q; Li W; Shi S; Guo L; Ying J; Zou S
Int J Cancer; 2020 Jun; 146(11):3077-3086. PubMed ID: 32030746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
